World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
80271
World Ranking
16845
National Ranking
8443

Overview

Fred D. Lublin is affiliated with the Icahn School of Medicine at Mount Sinai in the United States. Their primary research focuses on multiple sclerosis and related neurological disorders, with significant contributions to the understanding of disease mechanisms and clinical treatment outcomes.

The scientist's work spans a wide range of medical fields with a concentration in medicine, pathology and forensic medicine, neurology, rheumatology, molecular biology, and epidemiology. Their research topics prominently include multiple sclerosis research studies, peripheral neuropathies and disorders, rheumatoid arthritis research and therapies, polyomavirus and related diseases, SARS-CoV-2 and COVID-19 research, liver diseases and immunity, and autoimmune and inflammatory disorders research.

Recent publications by Fred D. Lublin highlight their involvement in multiple sclerosis research. Some notable papers are:

  • How patients with multiple sclerosis acquire disability, 2022, Brain
  • The 2013 clinical course descriptors for multiple sclerosis, 2020, Neurology

Though not a direct author on all recent influential papers in the field, they are associated with highly cited studies such as "Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study," published in 2021 in JAMA Neurology, demonstrating relevance in ongoing clinical trial research.

Fred D. Lublin frequently collaborates with other researchers in their field. Frequent co-authors include:

  • Gary Cutter
  • Sylvia Klineova
  • Bruce Cree
  • Stephen Krieger
  • Jerry S. Wolinsky

Publications are prominently featured in several scientific venues, including:

  • Neurology
  • Multiple Sclerosis and Related Disorders
  • Multiple Sclerosis Journal
  • The American Journal of Gastroenterology
  • Brain

Best Publications

  • Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

    Chris H Polman;Stephen C Reingold;Brenda Banwell;Michel Clanet

  • Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis

    W. Ian McDonald;Alistair Compston;Gilles Edan;Donald E Goodkin

  • Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

    Alan J. Thompson;Brenda L. Banwell;Frederik Barkhof;Frederik Barkhof;William M. Carroll

  • Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

    Chris H. Polman;Stephen C. Reingold;Gilles Edan;Massimo Filippi

  • Defining the clinical course of multiple sclerosis Results of an international survey

    Fred D. Lublin;Stephen C. Reingold

  • A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

    Chris H. Polman;Eva Havrdova;Michael Hutchinson;Ludwig Kappos

  • Defining the clinical course of multiple sclerosis: The 2013 revisions

    Fred D. Lublin;Stephen C. Reingold;Jeffrey A. Cohen;Gary R. Cutter

  • Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

    Stephen L. Hauser;Amit Bar-Or;Giancarlo Comi;Gavin Giovannoni

  • Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

    Xavier Montalban;Stephen L. Hauser;Ludwig Kappos;Douglas L. Arnold

  • Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

    Richard A. Rudick;William H. Stuart;Peter A. Calabresi;Christian Confavreux

  • Development of a multiple sclerosis functional composite as a clinical trial outcome measure

    Gary R. Cutter;Monika L. Baier;Richard A. Rudick;Diane L. Cookfair

  • New multiple sclerosis phenotypic classification.

    Fred D. Lublin

  • Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.

    D. S. Goodin;Elliot Frohman;G. P. Garmany;J. Halper

  • Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

    Peter A. Calabresi;Ernst Wilhelm Radue;Douglas Goodin;Douglas Jeffery

  • Differential diagnosis of suspected multiple sclerosis: a consensus approach

    D. H. Miller;B. G. Weinshenker;M. Filippi;B. L. Banwell

  • Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.

    Bruce A C Cree;Jeffrey L Bennett;Ho Jin Kim;Brian G Weinshenker

  • Effect of relapses on development of residual deficit in multiple sclerosis

    Fred D. Lublin;Monika Baier;Gary Cutter

  • Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis

    D. H. Miller;P. S. Albert;F. Barkhof;G. Francis

  • Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial

    Jerry S. Wolinsky;Ponnada A. Narayana;Paul O'Connor;Patricia K. Coyle

  • Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force

    Richard Rudick;Jack Antel;Christian Confavreux;Gary Cutter

Frequent Co-Authors

Jerry S. Wolinsky
Jerry S. Wolinsky The University of Texas Health Science Center at Houston
Ludwig Kappos
Ludwig Kappos University Hospital of Basel
Gary Cutter
Gary Cutter University of Alabama at Birmingham
Chris H. Polman
Chris H. Polman VU University Medical Center
Gavin Giovannoni
Gavin Giovannoni Queen Mary University of London
Eva Havrdova
Eva Havrdova Charles University
Matilde Inglese
Matilde Inglese University of Genoa
Peter A. Calabresi
Peter A. Calabresi Johns Hopkins University School of Medicine
Xavier Montalban
Xavier Montalban Autonomous University of Barcelona
Hans-Peter Hartung
Hans-Peter Hartung Heinrich Heine University Düsseldorf

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative or supplemental degrees can open new doors in the medical field, even if you aren’t pursuing a traditional MD or DO in the USA. Many students consider online healthcare degrees for greater flexibility and faster career advancement. For instance, those interested in healthcare administration can benefit from choosing a cahme accredited online mha program, which ensures the degree meets rigorous quality standards and is respected by employers nationwide.

Registered nurses aiming to expand their qualifications often look for the best online rn to bsn programs without clinical requirements. These options allow nurses to balance work, family, and study while accelerating their academic progress. Similarly, those seeking leadership and advanced practice roles may choose accelerated msn to dnp programs to obtain the highest nursing credentials more quickly.

For professionals keen to avoid traditional clinical rotations, there are also online dnp programs without clinicals. These alternatives are ideal for nurses and administrators looking to upskill or move into advanced positions remotely, offering convenience without sacrificing educational quality.

Best Scientists Citing Fred D. Lublin

Trending Scientists